Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2017 | Retinal Disorders

Plasma E-selectin levels can play a role in the development of diabetic retinopathy

Authors: Márta Kasza, J. Meleg, J. Vardai, B. Nagy Jr., E. Szalai, J. Damjanovich, A. Csutak, B. Ujhelyi, V. Nagy

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2017

Abstract

Purpose

Diabetic retinopathy is one of the leading causes of blindness. There are several risk factors, such as the duration of diabetes or glycemic control of the patient; however, several biochemical factors also alter the process. Our aim was to investigate the role of soluble E-selectin in the formation of diabetic retinopathy.

Patients and methods

Fifty-seven patients (37 female and 20 male, aged 61.71 ± 12.31 years) and 14 healthy control subjects (ten female and four male, aged 63.06 ± 10.46 years) were enrolled in the study. We measured the soluble E-selectin level in the plasma of patients by ELISA. All patients underwent careful ophthalmological examination, including ophthalmoscopy and color fundus photography, while diabetic retinopathy grading was performed in line with the 2012 classification of the American Academy of Ophthalmology (AAO).

Results

The soluble E-selectin level was significantly higher in patients with diabetes compared to controls (32.95 ng/ml vs. 26.55 ng/ml, p = 0.03). Dividing patients into groups by the presence of retinopathy, the E-selectin level was also significantly higher in the retinopathy group (p < 0.05). When we examined diabetic patients by the severity of retinopathy (groups A, B, and C, by the guidelines of the AAO), however, we did not find any significant difference in soluble E-selectin levels, although it tended to be higher in group B.

Conclusions

An elevated E-selectin level can play a role in the development of diabetic retinopathy, but it does not seem to alter disease severity. However, glycemic control and the reduction of cardiovascular risk factors may also alter the level of E-selectin that might play a role in the prevention of diabetic retinopathy.

Jonas JB, Bourne RR, White RA, Flaxmen SR, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Price H, Wong TY, Resnokoff S, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease Study (2014) Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis. Am J Ophthalmol 158(4):808–815CrossRefPubMed

Bhagat N, Grigorian RA, Tutela A, Zarbin MA (2009) Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54(1):1–32CrossRefPubMed

Davis MD, Fisher MR, Gangnon RE et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report number 18. Invest Ophthalmol Vis Sci 39:233–252PubMed

American Academy of Ophthalmology (2008) American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA. 4th printing 2012:5–6

Tedder TF, Steeber DA, Chen A, Engel P (1995) The selectins: vascular adhesion molecules. FASEB J 9:866–873PubMed

Schröder S, Palinski W, Schmid-Schönbein GW (1991) Activated monocytes and granulocytes, capillary nonperfusion and neovascularization in diabetic retinopathy. Am J Pathol 139:81–100PubMedPubMedCentral

Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 224(1):8–15CrossRefPubMed

Boulbou MS, Koukoulis GN, Makri ED, Petinaki EA, Gourgoulianis KI, Germenis AE (2005) Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol 98:39–44CrossRefPubMed

De Caterina R, Ghiadoni L, Taddei S, Virdis A, Almerigogna F, Basta G et al (2001) Soluble E-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens 14:259–266CrossRefPubMed

10.

Buemi M, Allegra A, Aloisi C, Corica F, Alonsi A, Ruello A et al (1997) Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. Hypertension 30:845–847CrossRefPubMed

11.

Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto A et al (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:4219–4225CrossRefPubMed

12.

Jager A, Hinsbergh V, Kostense PJ, Emeis J, Nijpels G, Dekker J et al (2000) Increased levels of soluble vascular cell adhesion molecule-1 are associated with risk of cardiovascular mortality in type 2 diabetes. The Hoorn Study. Diabetes 49:485–491CrossRefPubMed

13.

Hackman A, Abe Y, Insull W Jr et al (1996) Levels of soluble cell adhesion molecules in patients with dyslipidaemia. Circulation 93:1334–1338CrossRefPubMed

14.

Huang Z, Yin Q, Sun W, Zhu W, Li Y, Liu W, Xiao L, Duan Z, Cai Q, Liu D, Ma M, Liu X (2013) Microbleeds in ischemic stroke are associated with lower serum adiponectin and higher soluble E-selectin levels. J Neurol Sci 334(1–2):83–87CrossRefPubMed

15.

Richard S, Lagerstedt L, Burkhard PR, Debouverie M, Turck N, Sanchez J (2015) E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases. J Inflamm 12:61CrossRef

16.

Schmidt A, Crandall J, Hori O, Cao R, Lakatta E (1996) Elevated plasma cells of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol 92:747–750CrossRefPubMed

17.

Steiner M, Reinhardt MK, Krammer B, Ernst B, Blann AD (1994) Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 72:979–984PubMed

18.

Cominacini L, Pasini AF, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, Lo Cascio V (1995) Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 38:1122–1124CrossRefPubMed

19.

Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausl W, Wagner OF (1996) Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4313–4317PubMed

20.

Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S (1998) Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet Med 15:661–667CrossRefPubMed

21.

Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyake S (2002) Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 19:822–826CrossRefPubMed

22.

Blüher M, Unger R, Rassoul F, Richter V, Paschke R (2002) Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II. diabetes. Diabetologia 45:210–216CrossRefPubMed

23.

Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S (2002) Serum concentrations of soluble adhesion molecules are related to degree of hyperglycaemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 55:131–138CrossRefPubMed

24.

Fasching P, Waldhausl W, Wagner OF (1996) Elevated circulating adhesion molecules in NIDDM. Potential mediators in diabetic macroangiopathy. Diabetologia 39:1242–1244CrossRefPubMed

25.

Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A et al (1996) Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients. The possible role of metabolic control and oxidative stress. Metabolism 45:498–501CrossRefPubMed

26.

Cominacini L, Pasini AF, Garbin U, Campagnola M, Davoli A, Rigoni A et al (1997) E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients. Possible role of oxidative stress. Diabetologia 40:584–589CrossRefPubMed

27.

Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S (1997) Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 46:2096–2101CrossRefPubMed

28.

Olson JA, Whitelaw CM, McHardy KC, Pearson DWM, Forrester JV (1997) Soluble leukocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia 40:1166–1171CrossRefPubMed

29.

Limb GA, Hickman-Casey J, Hollifield RD, Chigneli AH (1999) Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 40:2453–2457PubMed

30.

Tang S, Le-Ruppert KC, Gabel VP (1994) Expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on proliferating vascular endothelial cells in diabetic epiretinal membranes. Br J Ophthalmol 78:370–376CrossRefPubMedPubMedCentral

31.

Boulbou MS, Koukoulis GN, Petinaki EA, Germenis A, Gourgoulianis KI (2004) Soluble adhesion molecules are not involved in the development of retinopathy in type 2 diabetic patients. Acta Diabetol 41:118–122CrossRefPubMed

32.

Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A, Nomura S (2015) Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 8:339–345PubMedPubMedCentral

33.

Nomura S, Omoto S, Yokoi T, Fujita S, Ozasa R, Eguchi N, Shouzu A (2011) Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med 4:539–545CrossRefPubMedPubMedCentral

34.

Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P (2014) Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism 63:1141–1148CrossRefPubMed

Title: Plasma E-selectin levels can play a role in the development of diabetic retinopathy
Authors: Márta Kasza
J. Meleg
J. Vardai
B. Nagy Jr.
E. Szalai
J. Damjanovich
A. Csutak
B. Ujhelyi
V. Nagy
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3411-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasma E-selectin levels can play a role in the development of diabetic retinopathy

Abstract

Purpose

Patients and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Erratum to: Compared antioxidant activity among corticosteroids on cultured retinal pigment epithelial cells

Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France

Intraoperative floppy iris syndrome and its association with various concurrent medications, bulbus length, patient age and gender

Intraretinal changes in the presence of epiretinal traction

En face Integrated Central Avascular Zone (EFICAZ): a noninvasive tool for correlating morphological and functional damage in central diabetic macular edema

Arterial stiffness shown by the cardio-ankle vascular index is an important contributor to optic nerve head microcirculation